N-(4-哌啶基)苯甲酰胺衍生物的设计、合成及其抗肝癌活性

doi:10.11944/j.issn.1000-0518.2016.06.150358

摘要/Abstract

摘要：

以4-羟基苯甲酸乙酯为原料,经烃化、水解、缩合、脱保护、磺酰化反应,合成了6个含有磺酰基取代的4-苯氧基-N-(4-哌啶基)苯甲酰胺衍生物。其结构经¹H NMR、¹³C NMR和MS谱等技术手段进行了表征,并以索拉非尼为阳性对照药对HepG2细胞株进行了初步体外抗肝癌细胞增殖活性的评价。实验发现,4-苯氧基-N-(1-甲磺酰基哌啶-4-基)苯甲酰胺的体外抗肝癌生物活性优于索拉非尼,IC₅₀值为8.42 μmol/L。研究结果表明,新结构4-苯氧基-N-(4-哌啶基)苯甲酰胺类化合物具有良好的抗肝癌活性。

关键词: 苯甲酰胺, HepG2细胞, 抗肝癌活性

Abstract:

Six benzamide derivatives were synthesized from 4-hydroxybenzoic acid via alkylation, hydrolysis and condensation reactions. The structure was confirmed by ¹H NMR, ¹³C NMR and MS. The antitumor activity of all the newly synthesized compounds was evaluated on the in vitro growth of HepG2 cell line using sorafeinb as positive control. The anti-hepatoma biological activity in vitro of N-(1-(methylsulfonyl)piperidin-4-yl)-4-phenoxybenzamide is better than that of sorafeinb with an IC₅₀ value of 8.42 μmol/L. The results show that the derivatives of N-(piperidin-4-yl)-4-phenoxybenzamide have good anti-hepatoma activity.

Key words: benzamide, HepG2 cells, anti-hepatoma activity

黄志宁, 郑满意, 苗方笑, 于婧琦, 李善花, 李福男, 曲宁. N-(4-哌啶基)苯甲酰胺衍生物的设计、合成及其抗肝癌活性[J]. 应用化学, 2016, 33(6): 661-667.

HUANG Zhining, ZHENG Manyi, MIAO Fangxiao, YU Jingqi, LI Shanhua, LI Funan, QU Ning. Synthesis and Anti-hepatoma Activities of N-(Piperidin-4-yl)benzamide Derivatives[J]. Chinese Journal of Applied Chemistry, 2016, 33(6): 661-667.

参考文献

[1]	CHEN Wanqing,ZHANG Siwei,ZENG Hongmei,et al.Report of Cancer Incidence and Mortality in China 2010[J]. China Cancer,2014,23(1):1-10(in Chinese). 陈万青,张思维,曾红梅,等. 中国2010年恶性肿瘤发病与死亡[J]. 中国肿瘤,2014,23(1):1-10.
[2]	CHEN Jianguo. Trends in the Incidence of Liver Cancer and Its Primary Prevention in China[J]. J Clin Hepatol,2012,28(4):256-260(in Chinese). 陈建国. 中国肝癌发病趋势和一级预防[J]. 临床肝胆病杂志,2012,28(4):256-260.
[3]	Ueno M,Uchiyama K,Ozawa S,et al.Adjuvant Chemolipiodolization Reduces Early Recurrence Derived from Intrahepatic Metastasis of Hepatocellular Carcinoma after Hepatectomy[J]. Ann Surg Oncol,2011,18(13):3624-3631.
[4]	WANG Fang,FU Liwu. Research Advances in Sorafenib:A Multiple Targeted Anti-tumor Agent[J]. Chinese Pharmacol Bull,2008,24(8):1117-1120(in Chinese). 王芳, 符立梧. 多靶点抗肿瘤新药索拉非尼的研究进展[J]. 中国药理学通报,2008,24(8):1117-1120.
[5]	Scott W,Christopher C,Mark L,et al.Discovery and Development of Sorafenib:A Multikinase Inhibitor for Treating Cancer[J]. Nat Rev Drug Discov,2006,5(10):835-844.
[6]	Yang S M,Huang Z N,Zhou Z S,et al.Structure-based Design, Structure-Activity Relationship Analysis, and Antitumor Activity of Diaryl Ether Derivatives[J]. Arch Pharm Res,2015,38(10):1761-1773.
[7]	Hou J,Zhao W,Huang Z N,et al.Evaluation of Novel N-(Piperidin-4-yl) benzamide Derivativesas Potential Cell Cycle Inhibitors in HepG2 Cells[J]. Chem Biol Drug Des,2015,86(2):223-231.
[8]	Lobb K,Hipskind P,Aikins J,et al.Acyl Sulfonamide Anti-Proliferatives:Benzene Substituent Structure-Activity Relationships for a Novel Class of Antitumor Agents[J]. J Med Chem,2004,47(22):5367-5380.
[9]	Bouchain G,Leit S,Frechette S,et al.Development of Potential Antitumor Agents. Synthesis and Biological Evaluation of a New Set of Sulfonamide Derivatives as Histone Deacetylase Inhibitors[J]. J Med Chem,2003,46(5):820-830.
[10]	LIU Fei,LIU Nan,HE Ling. Synthesis and Antitumor Activities of Sulfonyl Amidine Derivatives[J]. Chinese J Synth Chem,2014,22(4):440-443(in Chinese). 刘菲,刘楠,何菱. 磺酰脒衍生物的合成及其抗肿瘤活性[J]. 合成化学,2014,22(4):440-443.
[11]	Yang Y,Wang Z,Yang J,et al.Design, Synthesis and Evaluation of Novel Molecules with a Diphenyl Ether Nucleus as Potential Antitubercular Agents[J]. Bioorg Med Chem Lett,2012,22(2):954-957.
[12]	Gamet-Payrastre L,Li P,Lumeau S,et al.Sulforaphane, a Naturally Occurring Isothiocyanate, Induces Cell Cycle Arrest and Apoptosis in HT29 Human Colon Cancer Cells[J]. Cancer Res,2000,60(5):1426-1433.